Decision Resources is the premier provider of analysis and data on the significant issues facing the biopharmaceutical industry.
Three therapies, Teva’s Huntexil, Auspex’s SD-809 and Raptor’s Procysbi, will likely receive regulatory approval for Huntington’s disease in the United States and the EU5 markets... Learn More
Join us live on September 10, 2014... Learn More
View Webinar schedule and archive
See which reports have been searched on the most.
Come join us for an exciting one-day seminar.
Hear in-depth analysis of hot topics and trends concerning global oncology while engaging directly with Decision Resources Group analysts.
View the Agenda | Meet our expert speakers
August 27, 2014
Population Health Management Will Expand to More Type 2 Diabetes Patients
August 21, 2014
Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify
Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms
August 20, 2014
Payers Exert Cost Controls on High-Cost Biologics to Treat Autoimmune Conditions
Hospital-Treated Gram-Negative Infections - 2014
Gram-negative infections (GNIs) comprise a large portion of hospital-treated infections (HTIs), which represent a... Read More
Alzheimer's Disease - 2014
Last Updated 28 August 2014The market for Alzheimer’s disease (AD) pharmacotherapies continues to offer... Read More
Treatment Algorithms in Diabetic Macular Edema
Diabetic retinopathy (DR) is characterized by progressive damage to the blood vessels in the retina of a diabetic... Read More